Print Share

A monoclonal antibody against TNF alpha, a powerful promoter of inflammation.

Institution:

New York University School of Medicine

Researchers:

Jan Vilcek, MD, PhD, NYU School of Medicine

Impact:

Collaborating with the biotechnology company Centocor, Dr. Vilcek helped to develop the biologic drug known commercially as Remicade. To date, Remicade has been used to treat over a million patients worldwide for conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, plaque psoriasis, and ulcerative colitis.

Timeline:

1989

Topics

AgingBasic ScienceCancerCardiovascularClinical ResearchDiagnosticsDrug DevelopmentFeaturedGeneticsImmune SystemInfectious DiseaseMedical DeviceMental HealthNeurodegenerativeNobel PrizePediatricsPublic HealthRespiratorySurgical AdvancementTechnologyTreatment AdvancesVaccines

Schools

Albany Medical CollegeAlbert Einstein College of MedicineCity University of New York School of MedicineColumbia University College Of Physicians and SurgeonsHofstra Northwell School of Medicine at Hofstra UniversityIcahn School of Medicine at Mount SinaiJacobs School of Medicine and Biomedical Sciences, the University at BuffaloNew York Institute of Technology College of Osteopathic MedicineNew York Medical CollegeNew York University School of MedicineSchool of Medicine and Dentistry at the University of Rochester Medical CenterStony Brook University School of MedicineSUNY Downstate Medical CenterSUNY Upstate Medical UniversityTouro College of Osteopathic MedicineWeill Cornell MedicineWeill Cornell Medicine, NewYork-Presbyterian